The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia
(CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine,
Prevenar13, compared with a conventional 23-valent capsular polysaccharide vaccine in terms
of immune response.